QSIGHT TRACKER ALERTS

Guidepoint Qsight has been gathering insights from our panel of over 400 facilities to keep our customers informed and ahead of the curve. The below TRACKER Alerts capture procedure-specific trends and sentiments to help you get essential information quickly.

    Select TRACKER Alerts of Interest (check any that apply)

    Liquid Biopsy Market – August 2021
    Q3 2021 Expected Procedure Volumes TRACKER Alert - July 2021
    Spinal Cord Stimulation Procedures TRACKER Alert - June 2021
    Orladeyo for HAE and Tyvaso for PH-ILD TRACKER Alert - May 2021
    Revance Therapeutics TRACKER Alert - February 2021
    Orladeyo for HAE and Tyvaso for PH-ILD TRACKER Alert - January 2021
    Spinal Cord Stimulation Procedures TRACKER Alert - November 2020
    Medical Aesthetics TRACKER Alert - October 2020
    TAVR and TMVR Procedures TRACKER Alert - October 2020
    HAE TRACKER Alert - September 2020
    Robotic-Assist Surgery Systems TRACKER Alert - September 2020
    PAH TRACKER Alert - August 2020

    For more detail about our TRACKER Alerts, complete the form below and a member of the team will be in touch with more information.


    TRACKER Alert on the Liquid Biopsy Market – August 2021

    Insights in the report include:

    • Current usage of liquid and tissue biopsies
    • Liquid biopsy market analysis by product
    • Liquid biopsy tests ordered by cancer-type, primary clinical application, and reason
    • Liquid biopsy test shortcomings and overall product satisfaction
    • Forward-looking expected unit-share shifts by product

    TRACKER Alert on Q3 2021 Expected Procedure Volumes – July 2021

    Insights in the report include:

    • Expected Q3 procedure growth rates by market, weighted by practice volume
    • Estimated manufacturer unit share shifts for Q3 vs. Q2 2021
    • Qualitative verbatim responses providing further context into the expected Q3 volumes

    TRACKER Alert on Spinal Cord Stimulation Procedures – June 2021

    Insights in the report include:

    • Factors influencing future SCS procedures volumes
    • Senza Omnia, Intellis DTM, Spectra Wavewriter Alpha, Nalu product attribute ratings
    • Perspectives on anticipated SCS product launches
    • Expected procedure growth per expanded clinical indication

    TRACKER Alert on Orladeyo for HAE and Tyvaso for PH-ILD – May 2021 

    Insights in the report include:

    • Physician ratings on all the FDA approved HAE drugs including the newly approved Orladeyo
    • Anticipated switch to Orladeyo from Cinryze, Haegarda, and Takhzyro in 2021
    • Estimated percentage of patients appropriate for Tyvaso
    • Anticipated usage of Tyvaso by year-end 2021, 2022, and 2023
    March TRACKER Alert

    TRACKER Alert on Revance Therapeutics (RVNC) – February 2021 

    Insights in the report include:

    • Market penetration and usage of RHA products
    • Perception and anticipated use of DAXI
    • Expected shifts in unit share for dermal fillers and neurotoxins through 2022
    • Allergan-Evolus ITC Ruling Perspectives

    TRACKER Alert on Orladeyo for HAE and Tyvaso for PH-ILD – January 2021 

    Insights in the report include:

    • Physician ratings on all the FDA approved HAE drugs including the newly approved Orladeyo
    • Anticipated switch to Orladeyo from Cinryze, Haegarda, and Takhzyro in 2021
    • Estimated percentage of patients appropriate for Tyvaso
    • Anticipated usage of Tyvaso by year-end 2021, 2022, and 2023

    TRACKER Alert on Spinal Cord Stimulation Procedures – November 2020 

    Insights in the report include:

    • Current and expected SCS product usage and procedure trends
    • Senza Omnia vs. Intellis DTM product attributes
    • Perspectives on anticipated SCS product launches
    • Expected procedure growth per expanded clinical indication

    TRACKER Alert on Medical Aesthetics – October 2020 

    Insights in the report include:

    • Current RHA product usage and expected market penetration
    • Awareness and perception of anticipated DAXI launch
    • Expected shifts in unit share for dermal fillers and neurotoxins given Revance’s product portfolio
    • Factors influencing future product usage
    April TRACKER Alert
    June TRACKER Alert

    TRACKER Alert on TAVR and TMVR Procedures – October 2020

    Insights in the report include:

    • Current and expected TAVR procedures by indication and patient-risk
    • TAVR and MitraClip patient backlog in September 2020
    • Expected shifts in patient volume and product usage in Q4 2020
    • Anticipated clinical breakthroughs in TAVR and TMVR markets

    TRACKER Alert on HAE – September 2020

    Insights in the report include:

    • Satisfaction with current HAE treatments
    • Awareness of new HAE products in development
    • Likelihood of switching to new pipeline products when approved and available
    • Percentage of currently treated HAE patients who would switch to pipeline products, by current treatment
    July TRACKER Alert
    August TRACKER Alert

    TRACKER Alert on Ortho Robotic-Assist Surgery Systems – September 2020

    Insights in the report include:

    • Attitudes towards robotic-assisted surgeries vs. traditional surgical approaches
    • Expectations for increased robotics use at practice in the future
    • Likelihood of a purchasing robotics system in the future
    • Impact of COVID-19 on robotics usage within the practice

    TRACKER Alert on PAH Market – August 2020

    Insights in the report include:

    • Current landscape of PAH patients in TRACKER data by drug class and year-over-year changes in patient volumes
    • Awareness of PAH pipeline treatments
    • Likelihood of future use of pipeline treatments
    • Awareness and perception of Remunity pump
    May TRACKER Alert
    TRACKER Alert and the data contained therein are proprietary to Guidepoint and may not be shared with any third party.
    Guidepoint is not a registered investment adviser and cannot transact business as an investment adviser or give investment advice. This website and any information provided herein is provided for informational purposes only and is not intended to constitute investment advice, nor is it intended as an offer or solicitation of an offer or a recommendation to buy, hold or sell any security. Such information is obtained from third parties and does not necessarily represent the statements, views or opinions of Guidepoint or any Guidepoint employee. This website contains information that Guidepoint believes to be reliable, but neither Guidepoint nor its employees warrant its completeness or accuracy and shall not be responsible for any errors or omissions that may be contained therein.
    Privacy Preferences
    When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.